.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

AAN 2020: Multiple Sclerosis Treatment Considerations

EP. 1: Multiple Sclerosis and Risk of COVID-19

May 22nd 2020

EP. 2: Disease-Modifying Therapies for MS During COVID-19

May 22nd 2020

EP. 3: AAN 2020: Real-World Data on Cladribine Tablets for MS

May 22nd 2020

EP. 4: Multiple Sclerosis: Takeaways From AAN 2020

May 22nd 2020

EP. 5: MS Treatment Optimization During COVID-19

May 22nd 2020

EP. 6: Treating Patients With MS During the COVID-19 Pandemic

May 22nd 2020

EP. 7: AAN 2020 Data Release: Ofatumumab for Relapsing MS

May 22nd 2020

EP. 8: Novel Oral Therapy for MS: AAN Data Updates

May 22nd 2020

EP. 9: The Future of Multiple Sclerosis Management

May 22nd 2020

Latest News

Crenezumab Does Not Reduce Clinical Decline in Adults With Early Alzheimer Disease

Advancing the Treatment Paradigm for Myasthenia Gravis and Looking Toward the Future

Institutional Perspectives in Neurology, Chaired by Riley Bove, MD

Majority of Canadian Physicians Treat Primary Headache Disorders With Nonsteroidal Anti-inflammatory Drugs, Dopamine Receptor Antagonists

View More News